Survey of treatment recommendations for anaplastic oligodendroglioma.

Abstract:

:Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by experts in neuro-oncology. A Web-based survey was developed and distributed to 800 members of the Society of Neuro-Oncology (SNO) who had an e-mail address listed with SNO. Questions addressed use of molecular genetic information and treatment recommendations. A total of 99 clinical SNO members (20%) responded. The majority reported practicing at an academic center in the United States. Two-thirds of respondents see more than five patients with newly diagnosed anaplastic oligodendroglioma annually. Molecular genetic testing was requested for more than 75% of patients, and the results significantly influenced treatment recommendations (p = 0.000003). Regardless of molecular genetic status, the most commonly recommended treatment was the use of concurrent temozolomide and radiotherapy followed by adjuvant temozolomide (18%-34%). The current survey demonstrates that although neuro-oncologists have embraced the use of molecular genetic studies in newly diagnosed anaplastic oligodendroglioma, treatment recommendations vary widely and are often independent of the molecular data.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Abrey LE,Louis DN,Paleologos N,Lassman AB,Raizer JJ,Mason W,Finlay J,MacDonald DR,DeAngelis LM,Cairncross JG,Oligodendroglioma Study Group.

doi

10.1215/15228517-2007-002

subject

Has Abstract

pub_date

2007-07-01 00:00:00

pages

314-8

issue

3

eissn

1522-8517

issn

1523-5866

pii

15228517-2007-002

journal_volume

9

pub_type

杂志文章
  • A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.

    abstract::Difficulties of drug delivery across the blood-brain barrier (BBB) and failure to eliminate cancer stem cells (CSCs) are believed to be the major causes of tumor recurrences in children with medulloblastoma (MB). Seneca Valley virus-001 (SVV-001) is a naturally occurring oncolytic picornavirus that can be systemically...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq148

    authors: Yu L,Baxter PA,Zhao X,Liu Z,Wadhwa L,Zhang Y,Su JM,Tan X,Yang J,Adesina A,Perlaky L,Hurwitz M,Idamakanti N,Police SR,Hallenbeck PL,Blaney SM,Chintagumpala M,Hurwitz RL,Li XN

    更新日期:2011-01-01 00:00:00

  • Late relapse in primary central nervous system lymphoma: clonal persistence.

    abstract::Recurrence of primary central nervous system lymphoma (PCNSL) after initial diagnosis and treatment occurs within 2 years in most patients, and relapse after 5 years is rare. We evaluated late relapse in our PCNSL population. We identified 10 patients from our database of 378 patients (268 achieved a complete response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor014

    authors: Nayak L,Hedvat C,Rosenblum MK,Abrey LE,DeAngelis LM

    更新日期:2011-05-01 00:00:00

  • Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

    abstract::Treatment of malignant gliomas represents one of the most formidable challenges in oncology. The combination of surgery, radiation, and chemotherapy yields median survivals of less than one year. Here we demonstrate the use of a minimally invasive surgical technique, convection-enhanced delivery (CED), for local admin...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-001

    authors: Saito R,Krauze MT,Noble CO,Drummond DC,Kirpotin DB,Berger MS,Park JW,Bankiewicz KS

    更新日期:2006-07-01 00:00:00

  • PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

    abstract::We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogen...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2009-003

    authors: Perrone F,Da Riva L,Orsenigo M,Losa M,Jocollè G,Millefanti C,Pastore E,Gronchi A,Pierotti MA,Pilotti S

    更新日期:2009-12-01 00:00:00

  • PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

    abstract::The signaling pathways that underlie the pathogenesis of pediatric gliomas are poorly understood. We characterized the PI3K/Akt/mTOR pathway in pediatric gliomas of all grades. Using immunohistochemistry, we assessed activation of the PI3K/Akt/mTOR pathway by evaluating the downstream signaling molecules phospho(p)-S6...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos140

    authors: Mueller S,Phillips J,Onar-Thomas A,Romero E,Zheng S,Wiencke JK,McBride SM,Cowdrey C,Prados MD,Weiss WA,Berger MS,Gupta N,Haas-Kogan DA

    更新日期:2012-09-01 00:00:00

  • Coexpression of neuronatin splice forms promotes medulloblastoma growth.

    abstract::Medulloblastoma (MB) is the most common pediatric brain cancer. Several important developmental pathways have been implicated in MB formation, but fewer therapeutic targets have been identified. To locate frequently overexpressed genes, we performed a comprehensive gene expression survey of MB. Our comparison of 20 pr...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-038

    authors: Siu IM,Bai R,Gallia GL,Edwards JB,Tyler BM,Eberhart CG,Riggins GJ

    更新日期:2008-10-01 00:00:00

  • Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

    abstract:Background:Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens. Methods:We report the results of feasibility, phase I, and phase II studies of tandutinib (MLN518), an orally bioavailable inhibitor of type III...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/now185

    authors: Batchelor TT,Gerstner ER,Ye X,Desideri S,Duda DG,Peereboom D,Lesser GJ,Chowdhary S,Wen PY,Grossman S,Supko JG

    更新日期:2017-04-01 00:00:00

  • Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.

    abstract::Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge. Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning. Ten patients were enrolled. Eligibility criteria...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1215/15228517-2007-044

    authors: Stelzer KJ,Douglas JG,Mankoff DA,Silbergeld DL,Krohn KA,Laramore GE,Spence AM

    更新日期:2008-02-01 00:00:00

  • Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.

    abstract:Background:Craniopharyngiomas are neoplasms of the sellar/parasellar region that are classified into adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP) subtypes. Surgical resection of craniopharyngiomas is challenging, and recurrence is common, frequently leading to profound morbidity. BRAF ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy035

    authors: Coy S,Rashid R,Lin JR,Du Z,Donson AM,Hankinson TC,Foreman NK,Manley PE,Kieran MW,Reardon DA,Sorger PK,Santagata S

    更新日期:2018-07-05 00:00:00

  • DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

    abstract::We explored the associations of aberrant DNA methylation patterns in 12 candidate genes with adult glioma subtype, patient survival, and gene expression of enhancer of zeste human homolog 2 (EZH2) and insulin-like growth factor-binding protein 2 (IGFBP2). We analyzed 154 primary glioma tumors (37 astrocytoma II and II...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq190

    authors: Zheng S,Houseman EA,Morrison Z,Wrensch MR,Patoka JS,Ramos C,Haas-Kogan DA,McBride S,Marsit CJ,Christensen BC,Nelson HH,Stokoe D,Wiemels JL,Chang SM,Prados MD,Tihan T,Vandenberg SR,Kelsey KT,Berger MS,Wiencke JK

    更新日期:2011-03-01 00:00:00

  • Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.

    abstract:BACKGROUND:The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG). Prior studies showed that this metabolite can be detected in vivo using proton magnetic-resonance spectroscopy (MRS), but t...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov307

    authors: de la Fuente MI,Young RJ,Rubel J,Rosenblum M,Tisnado J,Briggs S,Arevalo-Perez J,Cross JR,Campos C,Straley K,Zhu D,Dong C,Thomas A,Omuro AA,Nolan CP,Pentsova E,Kaley TJ,Oh JH,Noeske R,Maher E,Choi C,Gutin PH,Ho

    更新日期:2016-02-01 00:00:00

  • Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation.

    abstract::Background Notch signaling is deregulated in human gliomas and may play a role in their malignancy. However, the role of each Notch receptor in glioma cell differentiation and progression is not clear. We examined the expression pattern of Notch receptors and compared it with differentiation markers in glioma cell lin...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not168

    authors: Dell'albani P,Rodolico M,Pellitteri R,Tricarichi E,Torrisi SA,D'Antoni S,Zappia M,Albanese V,Caltabiano R,Platania N,Aronica E,Catania MV

    更新日期:2014-01-01 00:00:00

  • The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death.

    abstract::The vasculature of 24 primary CNS B-cell lymphomas that were not related to acquired immunodeficiency syndrome was systematically studied by electron microscopy. Seven low-grade astrocytic tumors were included for comparison. Classical electron microscopy features of apoptosis were found in lymphoma cells of 21 of 22 ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/1.2.89

    authors: Molnár PP,O'Neill BP,Scheithauer BW,Groothuis DR

    更新日期:1999-04-01 00:00:00

  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

    abstract:BACKGROUND:RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS). METHODS:O...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1093/neuonc/not049

    authors: Boxerman JL,Zhang Z,Safriel Y,Larvie M,Snyder BS,Jain R,Chi TL,Sorensen AG,Gilbert MR,Barboriak DP

    更新日期:2013-07-01 00:00:00

  • Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

    abstract::Transforming growth factor-beta (TGF-beta) is a proinvasive and immunosuppressive cytokine that plays a major role in the malignant phenotype of gliomas. One novel strategy of disabling TGF-beta activity in gliomas is to disrupt the signaling cascade at the level of the TGF-beta receptor I (TGF-betaRI) kinase, thus ab...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-010

    authors: Tran TT,Uhl M,Ma JY,Janssen L,Sriram V,Aulwurm S,Kerr I,Lam A,Webb HK,Kapoun AM,Kizer DE,McEnroe G,Hart B,Axon J,Murphy A,Chakravarty S,Dugar S,Protter AA,Higgins LS,Wick W,Weller M,Wong DH

    更新日期:2007-07-01 00:00:00

  • Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma.

    abstract::In the present study we described the role of alpha9beta1 integrin in glioblastoma progression following its interaction with nerve growth factor (NGF). The level of expression of alpha9beta1 on astrocytomas is correlated with increased grade of this brain tumor and is highest on glioblastoma, whereas normal astrocyte...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-047

    authors: Brown MC,Staniszewska I,Lazarovici P,Tuszynski GP,Del Valle L,Marcinkiewicz C

    更新日期:2008-12-01 00:00:00

  • Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1.

    abstract:BACKGROUND:The transcription factor homeobox C9 (HOXC9) plays a crucial role in developmental regulatory systems, where it determines the specific positional identities of cells along the anteroposterior axis. The expression of HOXC9 has been found to be dysregulated in some cancers such as lung cancer, breast cancer, ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov281

    authors: Xuan F,Huang M,Liu W,Ding H,Yang L,Cui H

    更新日期:2016-06-01 00:00:00

  • Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study.

    abstract::The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1093/neuonc/2.4.213

    authors: Mahoney DH Jr,Cohen ME,Friedman HS,Kepner JL,Gemer L,Langston JW,James HE,Duffner PK,Kun LE

    更新日期:2000-10-01 00:00:00

  • Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

    abstract:BACKGROUND:Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classification-however, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinico...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not125

    authors: Laxton RC,Popov S,Doey L,Jury A,Bhangoo R,Gullan R,Chandler C,Brazil L,Sadler G,Beaney R,Sibtain N,King A,Bodi I,Jones C,Ashkan K,Al-Sarraj S

    更新日期:2013-12-01 00:00:00

  • Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

    abstract::Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Although there is monthly fluctuation of the white blood cell coun...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-046

    authors: Heimberger AB,Sun W,Hussain SF,Dey M,Crutcher L,Aldape K,Gilbert M,Hassenbusch SJ,Sawaya R,Schmittling B,Archer GE,Mitchell DA,Bigner DD,Sampson JH

    更新日期:2008-02-01 00:00:00

  • Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.

    abstract:Background:CNS tumors, including medulloblastoma and pediatric glioblastoma (pGBM) account for the majority of solid pediatric malignancies. There remains an unmet need to identify novel treatment approaches in poor prognosis and relapsed pediatric brain tumors, where therapeutic options are limited. Small-molecule B-c...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox134

    authors: Levesley J,Steele L,Brüning-Richardson A,Davison A,Zhou J,Ding C,Lawler S,Short SC

    更新日期:2018-01-22 00:00:00

  • Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.

    abstract:BACKGROUND:Diffuse intrinsic pontine glioma (DIPG) is associated with poor survival regardless of therapy. We used volumetric apparent diffusion coefficient (ADC) histogram metrics to determine associations with progression-free survival (PFS) and overall survival (OS) at baseline and after radiation therapy (RT). MET...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov256

    authors: Poussaint TY,Vajapeyam S,Ricci KI,Panigrahy A,Kocak M,Kun LE,Boyett JM,Pollack IF,Fouladi M

    更新日期:2016-05-01 00:00:00

  • Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

    abstract:BACKGROUND:Mutations involving isocitrate dehydrogenase 1 (IDH 1) occur in a high proportion of diffuse gliomas, with implications on diagnosis and prognosis. About 90% involve exon 4 at codon 132, replacing amino acid arginine with histidine (R132H). Rarer ones include R132C, R132S, R132G, R132L, R132V, and R132P. Mos...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not015

    authors: Agarwal S,Sharma MC,Jha P,Pathak P,Suri V,Sarkar C,Chosdol K,Suri A,Kale SS,Mahapatra AK,Jha P

    更新日期:2013-06-01 00:00:00

  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.

    abstract::This study estimated the maximum tolerated dose (MTD) of imatinib with irradiation in children with newly diagnosed brainstem gliomas, and those with recurrent malignant intracranial gliomas, stratified according to use of enzyme-inducing anticonvulsant drugs (EIACDs). In the brainstem glioma stratum, imatinib was ini...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-031

    authors: Pollack IF,Jakacki RI,Blaney SM,Hancock ML,Kieran MW,Phillips P,Kun LE,Friedman H,Packer R,Banerjee A,Geyer JR,Goldman S,Poussaint TY,Krasin MJ,Wang Y,Hayes M,Murgo A,Weiner S,Boyett JM

    更新日期:2007-04-01 00:00:00

  • The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.

    abstract:BACKGROUND:Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT promoter-enhancer single nucleotide polymorphism (SNP; rs16906252) has been associated with the presence of MGMT promoter methylation in other cancers. We ex...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov064

    authors: Rapkins RW,Wang F,Nguyen HN,Cloughesy TF,Lai A,Ha W,Nowak AK,Hitchins MP,McDonald KL

    更新日期:2015-12-01 00:00:00

  • EANO guidelines for the diagnosis and treatment of ependymal tumors.

    abstract::Ependymal tumors are rare CNS tumors and may occur at any age, but their proportion among primary brain tumors is highest in children and young adults. Thus, the level of evidence of diagnostic and therapeutic interventions is higher in the pediatric compared with the adult patient population.The diagnosis and disease...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox166

    authors: Rudà R,Reifenberger G,Frappaz D,Pfister SM,Laprie A,Santarius T,Roth P,Tonn JC,Soffietti R,Weller M,Moyal EC

    更新日期:2018-03-27 00:00:00

  • Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.

    abstract:BACKGROUND:Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were restricted to small sample sizes, often with patients at a specific institution. METHODS:Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed. Patients were all...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/nou162

    authors: Vera-Bolanos E,Aldape K,Yuan Y,Wu J,Wani K,Necesito-Reyes MJ,Colman H,Dhall G,Lieberman FS,Metellus P,Mikkelsen T,Omuro A,Partap S,Prados M,Robins HI,Soffietti R,Wu J,Gilbert MR,Armstrong TS,CERN Foundation.

    更新日期:2015-03-01 00:00:00

  • Response and progression in recurrent malignant glioma.

    abstract::In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1093/neuonc/1.4.282

    authors: Hess KR,Wong ET,Jaeckle KA,Kyritsis AP,Levin VA,Prados MD,Yung WK

    更新日期:1999-10-01 00:00:00

  • Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

    abstract:INTRODUCTION:Surgery is first-line therapy for glioblastoma, and there is evidence that gross total resection is associated with improved survival. Gross total resection, however, is not always possible, and relationships among extent (percent) of resection (EOR), residual volume (RV), and survival are unknown. The goa...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not137

    authors: Chaichana KL,Jusue-Torres I,Navarro-Ramirez R,Raza SM,Pascual-Gallego M,Ibrahim A,Hernandez-Hermann M,Gomez L,Ye X,Weingart JD,Olivi A,Blakeley J,Gallia GL,Lim M,Brem H,Quinones-Hinojosa A

    更新日期:2014-01-01 00:00:00

  • The genetic landscape of choroid plexus tumors in children and adults.

    abstract:BACKGROUND:Choroid plexus tumors (CPTs) are intraventricular brain tumors predominantly arising in children but also affecting adults. In most cases, driver mutations have not been identified, although there are reports of frequent chromosome-wide copy-number alterations and TP53 mutations, especially in choroid plexus...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa267

    authors: Thomas C,Soschinski P,Zwaig M,Oikonomopoulos S,Okonechnikov K,Pajtler KW,Sill M,Schweizer L,Koch A,Neumann J,Schüller U,Sahm F,Rauschenbach L,Keyvani K,Proescholdt M,Riemenschneider MJ,Segewiß J,Ruckert C,Grauer O,M

    更新日期:2020-11-29 00:00:00